Additionally, it may be a critical determinant for the observed growth advantage of CLL cells where TP53 is down‐regulated; once cells overcome cytokinesis and cell cycle defects, uncontrolled proliferation may be the consequence. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.